Physician
Holterman, Mark
Holterman, Mark was paid $1.54M by Medicaid between Mar 2021 and Dec 2024, across 42 billing codes. Its largest line is 87633, Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets — 31% of everything it billed.
33Billing provider infoHOLTERMAN, MARK
CHICAGO, IL 60612
CHICAGO, IL 60612
33aNPI1033168273assigned 05/06/2006
33bProvider typePediatric Surgery Physician
28Total paid$1.54M
24GClaims29,890
24DCodes billed42
24AFirst – last monthMar 2021 – Dec 2024
Compared with peers
Next to other Pediatric Surgery Physician providers in Illinois
Rank by total paid#1 of 14
Median peer was paid$4K
This provider vs. median437×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 9,116 | $674K | |
| 2022 | 9,573 | $481K | |
| 2023 | 5,681 | $182K | |
| 2024incomplete | 5,520 | $203K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 31% | 1,376 | 1,150 | $471K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 26% | 9,667 | 7,802 | $399K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 11% | 3,485 | 3,137 | $163K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 5.4% | 914 | 866 | $83K |
| 87486 | 4.1% | 1,369 | 1,139 | $62K | |
| 87581 | 4.0% | 1,367 | 1,137 | $62K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.9% | 3,870 | 3,362 | $60K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3.6% | 2,378 | 2,002 | $55K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.6% | 734 | 490 | $55K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 3.1% | 202 | 139 | $48K |
| 99000 | 1.5% | 974 | 794 | $23K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.2% | 763 | 519 | $19K |
30 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 878 | $9K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 35 | $5K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 192 | $5K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 104 | $4K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 39 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 39 | $2K |
| 81002 | <1% | 649 | $2K | |
| 0004A | <1% | 35 | $1K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 38 | $1K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 12 | $981.60 |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 16 | $836.18 |
| 0064A | <1% | 19 | $800.66 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 39 | $719.90 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 35 | $644.15 |
| 0002A | <1% | 15 | $632.10 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 111 | $582.66 |
| 80053 | Comprehensive metabolic panel | <1% | 57 | $580.17 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 28 | $446.32 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 12 | $338.90 |
| 84481 | <1% | 29 | $284.48 | |
| 90686 | <1% | 19 | $232.46 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 12 | $213.12 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 33 | $189.42 |
| 99072 | <1% | 16 | $175.00 | |
| 82607 | <1% | 14 | $168.00 | |
| 80061 | Lipid panel | <1% | 14 | $112.42 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 30 | $51.08 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 19 | $45.27 |
| 36415 | Collection of venous blood by venipuncture | <1% | 214 | $44.50 |
| 91300 | <1% | 38 | $0.12 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.